GSK joins Philip Morris-backed Medicago on plant-based Covid-19 vaccine
Human testing is due to start in mid-July and, if successful, the companies could manufacture about 100-million doses by the end of 2021
London — GlaxoSmithKline (GSK) is collaborating on an experimental Covid-19 vaccine with Medicago, a biotechnology company partly owned by tobacco giant Philip Morris International.
The partnership will combine Medicago’s plant-based production platform with GSK’s adjuvants — substances that enhance the body’s immune response — the companies said on Tuesday. Human testing is due to start in mid-July, and the companies aim to make the vaccine available in the first half of 2021, if it’s successful...